ClinicalTrials.gg
RecruitingNCT05339984LSMUpdated Jun 27, 2025

Hepatic and Systemic Hemodynamic Modeling During Liver Surgery

An interventional study of Partial hepatectomy (open approach) and liver transplantation in Liver Diseases and Liver Transplantation, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-27.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 69 studies in Liver Diseases with a site in France — 19 open to participants now, 24 under way, 4 of them phase 3. Liver Diseases · France.

Planned enrollment
20th of 49
150 · median 124
Started
2023
with 4 others
No phase
13 of 69
6 open now
Primary completion
2026-06
later than 3 of 23 live
Registered
47th of 69
by date
Lead sponsor
9 of 69
Assistance Publique - Hôpitaux de Paris

Among the 69 studies in Liver Diseases with a site in France, this one is the 20th largest by planned enrollment of the 49 interventional ones that give a count, is one of 5 that started in 2023, is one of 13 with no phase, reaches primary completion later than 3 of the 23 other live ones, and was the 47th registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

19 of the 69 studies in Liver Diseases with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 105 Liver Diseases studies recruiting now, 52 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Liver Diseases with a site in France, or all of them as a file.
02

Study summary

" Despite the medical and surgical progress of the last two decades, the selection of candidates for liver surgery remains based on old principles and insufficiently sensitive to fine-tune the gesture to patient-specific characteristics and make almost zero risks of postoperative liver failure (PLF) and death. It is therefore necessary to develop new tools that will make possible to predict the evolution of the postoperative portocaval gradient (difference of pressure between portal vein and vena cava), a well-known major risk factor for PLF. Hemodynamic modeling of the human liver during surgery will represent the purpose of this work in order to help the clinicians in their patient's selection and anticipation of postoperative risk.

The aim is to develop and validate an hemodynamics mathematical model to predict the evolution of the portocaval gradient in three surgical situations of increasing complexity: portal modulation by embolization, hepatectomy, and small partial graft liver transplantation.

The endpoints will be the estimation of the intraoperative post-procedural portocaval gradient and comparison of the estimated portocaval gradient with that measured at the end of the procedure. This pressure differential is performed before parietal closure, after surgery. "

Read the detailed description

"The surgical management of liver cancer is becoming increasingly complex, with resections often extensive, iterative and on pathological liver (cirrhosis or multi-chemotherapies). This attitude is made possible by a better selection and perioperative management of patients, as well as by the regenerative capacity of the liver. However, even if extensive resections are routinely performed, the limitation remains the risk of postoperative liver failure (PLF), especially in patients with chronic liver disease. Despite numerous known risk factors, some of which are avoidable, PLF and/or postoperative liver decompensation (ascites) remain frequent complications (incidence > 5%) and PLF remains one of the main causes of postoperative death.

The difficulty lies finally in the choice of a treatment adapted to the carcinological needs, with the balance between what is technically feasible and what will be tolerated on the functional and metabolic level. This balance is founded on a surgical evaluation based on objective elements (volumetry and biological tests in particular) and on the surgeon's experience. This estimate is imperfect, the proof being the mortality at 3 months after hepatectomies which is still high, 5 to 7% if considering all types of hepatectomies. It is obviously possible to further improve these results and the computer tool must find its place in the medical-surgical algorithm. It is already known that virtual (preoperative) 3D hepatic reconstructions are an important aid and lead to a decrease in postoperative morbidity and mortality but hemodynamic simulation could also be used as a decision-making tool.

After hepatectomy, the imperative to maintain a satisfactory liver function is to preserve a sufficient residual parenchymal volume associated with an intrahepatic blood supply (inflow) adapted to the volume of the liver and to the splanchnic flow, and a sufficient effluent (outflow) to avoid any intrahepatic congestion. The post-resection portocaval gradient is one of the most relevant reflections of the hemodynamic conditions of a liver and the risk of PLF but it is only available intraoperatively, after the surgical procedure has been performed, and therefore cannot be used as a tool for selecting candidates for surgery. Currently, there are several decision algorithms to guide the surgical management of a patient, based on preoperative clinical or biological data (platelets, bilirubin, indocyanine green clearance, ascites, esophageal varices...). The pre-resection portocaval gradient ≥10 mmHg, measured or estimated non-invasively, allows selection of high-risk patients, but remains not very sensitive and specific, and does not prevent the occurrence of any PLF.

It therefore remains very difficult for a given patient (especially cirrhotic) to accurately predict the risk of postoperative decompensation and some patients may sometimes be undertreated for fear of decompensation. In these patients, it is therefore a loss of chance.

In liver transplantation, the same need for adequacy between the vascular bed and the portal flow is necessary, especially in case of a small graft or partial liver. In case of mismatch, a small for size syndrome, i.e. portal hypertension (PHT) and organ failure (PLF equivalent) may occur, thus endangering the graft and the patient. As with partial hepatectomies, prediction of the post-transplant portocaval gradient would help avoid small-for-size syndrome by fine-tuning the maximum mass portal flow not to be exceeded. Thus, a better matching of the donor/recipient pair could be proposed, especially for living donor or auxiliary transplants.

Finally, portal embolization is a radiological procedure to prepare an organ for hepatectomy via atrophy on the embolized side and contralateral hypertrophy. Sometimes, especially in cirrhosis, portal embolization can be complicated by portal thrombosis, the main risk factor of which is the elevation of the portocaval gradient. Currently, there is no tool to anticipate this gradient and a 0D simulation would allow to avoid this risk by adjusting the embolized volume (seuential embolizations if needed).

In the end, and despite the medical-surgical progress of the last two decades, the selection of candidates for liver surgery remains based on old and insufficiently sensitive principles to finely adapt the procedure to the specific patient characteristics and minimize the postoperative risk. The aim of this study is to help surgeons in their decisions thanks to modern simulation tools that have never been tested in humains.

The proposed tool is a 0D model applied to liver surgery. It is based on ordinary differential equations: blood flows are represented by electric currents and blood pressures by electric voltages. It is called 0D because there is no space dimension in the equations.

Simulations and predictions will require:

  • Collection of preoperative data (imaging, biology, clinical,...).
  • Collection of intraoperative pre-procedural and post-procedural data: hemodynamic and biological measurements.
  • Collection of postoperative data (immediate postoperative follow-up, current biology, anatomopathology).

These pre-procedure data are used to adjust the model for each patient. Once the model is ""calibrated"" to the real conditions, the simulation of the intervention can be performed to predict the post-procedural data, and compare them to the real measurements, as well as correlate them to the post-procedural events.

Scheme: in a first phase, use of preoperative and intraoperative data to improve the 0D model initially developed in animals and tested in a pilot study in humans. Depending on the final accuracy of the algorithm, a validation of the algorithm will then be performed in a second phase.

Expected benefits for the participants: no benefit because no modification of the medical-surgical management based on the measurements performed. All the simulations will be performed after the surgery, in a retrospective way.

Expected benefits for the society (future patients):

  • Improved criteria for selecting organs or patients who are candidates for hepatectomy/transplantation/interventional radiology to minimize the risk of complications or death.
  • Possible improvement of surgical techniques (vascular anastomoses and liver positioning).

Procedure:

All potentially eligible patients will be asked to participate in the study during a preoperative visit performed as part of the care. Eligible patients who have signed the consent form will have protocol procedures performed as part of their care, such as flow MRI and ultrasound-based hepatic and cardiac flowmetry.

Protocol procedures will also be performed intraoperatively at the beginning and end of the procedure (hepatectomy, TH or portal embolization). Patients with hepatectomy or TH will have the same follow-up as the care at D7 and D30 post-procedure with ultrasound, CT scan, biological work-up and consultation with the surgeon.

Patients with portal embolization will also have the protocol procedures at the time of hepatectomy which will take place 4 to 6 weeks after portal embolization. These patients will be followed up 1 month after hepatectomy, at D7 and D30 post hepatectomy.

Statistical analysis:

LSM is an exploratory predictive model development and feasibility study, with no a priori hypothesis to test; therefore, the number of subjects needed is based on feasible inclusions over 36 months at the participating center. The potential inclusion is 50 patients per year, or 150 patients over 3 years. The study has two phases: a development and improvement phase of the 0D algorithm and a validation phase. In the first phase, the algorithm is tested as it is developed on an increasingly large cohort. At each test of the algorithm, the concordance between the porto-cavity gradient (PCG) measured postoperatively and the simulated PCG is calculated using the intraclass correlation coefficient and the Bland \& Altman graph. The completion of the second phase depends on the results of the first phase.

These numbers are consistent with the recruitment center being a high-volume referral center.

03

Conditions studied

  • Liver Diseases
  • Liver Transplantation

Keywords

  • Benign Liver Tumor
  • Primary Liver Tumor
  • Secondary liver tumor
  • Cirrhosis
  • Portal hypertension
  • small-for-size syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Liver pathology requiring minor or major hepatectomy by laparotomy, or transplantation with small livers (graft weight/patient weight ratio \< 0. 01) or partial livers (living donor recipient or auxiliary grafts) or portal embolization (all patients scheduled for major hepatectomy on cirrhosis, or expanded hepatectomy on non-cirrhotic liver if and only if the ratio of future remaining liver/body weight is \<0.5.
  • Membership in a social security plan
  • Written consent to participate in this research
  • Adult patients (age ≥18 years)

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Patient under guardianship or curatorship
  • Refusal to participate in the study
  • to performing of MRI.
  • Patient Under State medical aid
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Hepatectomy

    Liver resection group

    Procedure: Partial hepatectomy (open approach)

  • Experimental
    Liver Transplantation

    Liver Transplantation group

    Procedure: liver transplantation

  • Experimental
    Portal vein embolization

    Portal vein embolization group

    Procedure: Portal vein embolization

Interventions

  • ProcedurePartial hepatectomy (open approach)

    preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry

  • Procedureliver transplantation

    preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry

  • ProcedurePortal vein embolization

    preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry

06

What researchers measure

Primary outcomes

  1. Estimation of the intraoperative portocaval post-procedural gradient.

    The pressure differential is performed before the parietal closure, after resection. The simulation is accurate if the difference with the measurement is ≤ 3 mmHg.

    Time frame: measures performed during surgery.

Secondary outcomes

  1. Prediction of the evolution of portal pressure after surgery

    Time frame: measures performed during surgery.

  2. Prediction of the evolution of cardiac outpout after surgery

    Time frame: measures performed during surgery.

  3. Prediction of the evolution of hepatic artery and portal vein flows after surgery

    Time frame: measures performed during surgery.

07

Study locations

1 of 1 sites recruiting
  • Centre Hépato-Biliaire - Hôpital Paul Brousse
    Villejuif, Val de Marne 94800, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jun 2026, 40 months after the start.

Of 122 non-industry interventional studies with no phase under Liver Diseases, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's planned 40 months is above that.

Counting every sponsor, half of 135 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2022
First posted
Apr 21, 2022
StartActual
Jan 3, 2023
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Jun 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05339984
Collaborators
Institut National de Recherche en Informatique et en Automatique
Responsible party
Sponsor
First posted
Apr 21, 2022
Start date
Jan 3, 2023
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Jun 27, 2025

Study contacts

GOLSE Nicolas, M.D
Contact
nicolas.golse@aphp.fr
06 71 28 24 03
VIBERT Eric, M.D
Contact
eric.vibert@aphp.fr
06 60 64 96 97

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion